Summary
On 27 March 2020, Medicines Australia (MA) lodged an application for authorisation on behalf of itself and its members, and the Generic and Biosimilar Medicines Association (GBMA) and its members. MA seeks authorisation for an initial period of six months to implement a coordinated strategy in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic. MA also seeks urgent interim authorisation, in light of the current demands on the health system and in order to assist relevant government bodies.
On 3 April 2020, the ACCC granted interim authorisation.
The ACCC invites submissions in relation to the application for authorisation by 27 April 2020. For further information about the application, and how to provide a submission to the ACCC, please refer to the links below.
An indicative timetable is set out below for your information
|
Indicative date |
Stage in assessment process |
|
27 March 2020 |
Lodgement of application, including request for interim authorisation |
|
3 April 2020 |
ACCC decision on interim authorisation |
|
6 April 2020 |
Public consultation begins |
|
27 April 2020 |
Closing date for submissions |
|
18 May 2020 |
Applicant responds to issues raised in public consultation process |
|
June/July 2020 |
ACCC draft determination |
|
July/August 2020 |
Public consultation on the draft determination including any conference if called |
|
September 2020 |
Final determination |
Authorisation number(s)
- AA1000486-1